

ICD-10 CODING BOOKLET

Your resource to ICD-10 diagnosis coding for patients with established cardiovascular disease (CVD) or familial hypercholesterolemia (FH) who require additional lowering of LDL-C



Indications

Prevention of Cardiovascular Events: In adults with established cardiovascular disease, Repatha® is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization.

Primary Hyperlipidemia (including Heterozygous Familial Hypercholesterolemia): Repatha® is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).

Homozygous Familial Hypercholesterolemia: Repatha® is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.

The safety and effectiveness of Repatha® have not been established in pediatric patients with HoFH who are younger than 13 years old or in pediatric patients with primary hyperlipidemia or HeFH.

Important Safety Information

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Please [click here](#) to see additional Important Safety Information on page 17.

 **Repatha**[®]
(evolocumab) injection
140 mg/mL

Hyperlipidemia and Ischemic Heart Disease

Primary ICD-10 Codes

Disorders of lipoprotein metabolism and other lipidemias

- E78.00** Pure hypercholesterolemia, unspecified
- E78.01** Familial hypercholesterolemia
- E78.2** Mixed hyperlipidemia
- E78.4** Other hyperlipidemia
- E78.5** Hyperlipidemia, unspecified

Secondary ICD-10 Codes

Atherosclerosis and atherosclerotic heart disease

- I25.10** Atherosclerotic heart disease of native coronary artery without angina pectoris
- I25.110** Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
- I25.111** Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm
- I25.118** Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris
- I25.119** Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris
- I25.700** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris
- I25.701** Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm
- I25.708** Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris
- I25.709** Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris
- I25.710** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris
- I25.711** Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.718** Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris
- I25.719** Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris
- I25.720** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris
- I25.721** Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.728** Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris
- I25.729** Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris
- I25.730** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris
- I25.731** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.738** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris
- I25.739** Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris
- I25.750** Atherosclerosis of native coronary artery of transplanted heart with unstable angina
- I25.751** Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm

Important Safety Information

Allergic Reactions: Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please [click here](#) to see additional Important Safety Information on page 17.

Ischemic Heart Disease (*cont'd*)

- I25.758 Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris
- I25.759 Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris
- I25.760 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina
- I25.761 Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm
- I25.768 Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris
- I25.769 Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris
- I25.790 Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris
- I25.791 Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm
- I25.798 Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris
- I25.799 Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris
- I25.810 Atherosclerosis of coronary artery bypass graft(s) without angina pectoris
- I25.811 Atherosclerosis of native coronary artery of transplanted heart without angina pectoris
- I25.812 Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris

➤ Ischemic heart disease (other)

- I20.8 Other forms of angina pectoris
- I20.9 Angina pectoris, unspecified
- I23.7 Postinfarction angina
- I24.0 Acute coronary thrombosis not resulting in myocardial infarction
- I24.8 Other forms of acute ischemic heart disease
- I25.2 Old myocardial infarction
- I25.3 Aneurysm of heart
- I25.41 Coronary artery aneurysm
- I25.42 Coronary artery dissection
- I25.5 Ischemic cardiomyopathy
- I25.6 Silent myocardial ischemia
- I25.82 Chronic total occlusion of coronary artery
- I25.83 Coronary atherosclerosis due to lipid rich plaque
- I25.84 Coronary atherosclerosis due to calcified coronary lesion
- I25.89 Other forms of chronic ischemic heart disease
- I25.9 Chronic ischemic heart disease, unspecified

Important Safety Information

Adverse Reactions in Primary Hyperlipidemia, including HeFH: The most common adverse reactions (> 5% of Repatha[®]-treated patients and occurring more frequently than placebo) in clinical trials in primary hyperlipidemia (including HeFH) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please [click here](#) to see additional Important Safety Information on page 17.

Ischemic Heart Disease (*cont'd*) and Cerebrovascular Diseases



➤ **ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction**

- I21.01** ST elevation (STEMI) myocardial infarction involving left main coronary artery
- I21.02** ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery
- I21.09** ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall
- I21.11** ST elevation (STEMI) myocardial infarction involving right coronary artery
- I21.19** ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall
- I21.21** ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery
- I21.29** ST elevation (STEMI) myocardial infarction involving other sites
- I21.3** ST elevation (STEMI) myocardial infarction of unspecified site
- I21.4** Non-ST elevation (NSTEMI) myocardial infarction
- I22.0** Subsequent ST elevation (STEMI) myocardial infarction of anterior wall
- I22.1** Subsequent ST elevation (STEMI) myocardial infarction of inferior wall
- I22.2** Subsequent non-ST elevation (NSTEMI) myocardial infarction
- I22.8** Subsequent ST elevation (STEMI) myocardial infarction of other sites
- I22.9** Subsequent ST elevation (STEMI) myocardial infarction of unspecified site

➤ **Presence of cardiac and vascular implants and grafts and other postprocedural states**

- Z95.1** Presence of aortocoronary bypass graft
- Z95.5** Presence of coronary angioplasty implant and graft
- Z98.61** Coronary angioplasty status

➤ **Occlusion and stenosis of precerebral and cerebral arteries, not resulting in cerebral infarction**

- I65.01** Occlusion and stenosis of right vertebral artery
- I65.02** Occlusion and stenosis of left vertebral artery
- I65.03** Occlusion and stenosis of bilateral vertebral arteries
- I65.09** Occlusion and stenosis of unspecified vertebral artery
- I65.1** Occlusion and stenosis of basilar artery
- I65.21** Occlusion and stenosis of right carotid artery
- I65.22** Occlusion and stenosis of left carotid artery
- I65.23** Occlusion and stenosis of bilateral carotid arteries
- I65.29** Occlusion and stenosis of unspecified carotid artery
- I65.8** Occlusion and stenosis of other precerebral arteries
- I65.9** Occlusion and stenosis of unspecified precerebral artery
- I66.01** Occlusion and stenosis of right middle cerebral artery
- I66.02** Occlusion and stenosis of left middle cerebral artery
- I66.03** Occlusion and stenosis of bilateral middle cerebral arteries
- I66.09** Occlusion and stenosis of unspecified middle cerebral artery
- I66.11** Occlusion and stenosis of right anterior cerebral artery
- I66.12** Occlusion and stenosis of left anterior cerebral artery

Important Safety Information

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Please [click here](#) to see additional Important Safety Information on page 17.

Cerebrovascular Diseases (*cont'd*)

- I66.13** Occlusion and stenosis of bilateral anterior cerebral arteries
- I66.19** Occlusion and stenosis of unspecified anterior cerebral artery
- I66.21** Occlusion and stenosis of right posterior cerebral artery
- I66.22** Occlusion and stenosis of left posterior cerebral artery
- I66.23** Occlusion and stenosis of bilateral posterior cerebral arteries
- I66.29** Occlusion and stenosis of unspecified posterior cerebral artery
- I66.3** Occlusion and stenosis of cerebellar arteries
- I66.8** Occlusion and stenosis of other cerebral arteries
- I66.9** Occlusion and stenosis of unspecified cerebral artery

➤ Cerebrovascular diseases (other)

- I67.2** Cerebral atherosclerosis
- I67.5** Moyamoya disease
- I67.81** Acute cerebrovascular insufficiency
- I67.82** Cerebral ischemia
- I67.89** Other cerebrovascular disease
- I67.9** Cerebrovascular disease, unspecified
- I68.0** Cerebral amyloid angiopathy
- I68.8** Other cerebrovascular disorders in diseases classified elsewhere

➤ Cerebral infarction

- I63.00** Cerebral infarction due to thrombosis of unspecified precerebral artery
- I63.011** Cerebral infarction due to thrombosis of right vertebral artery
- I63.012** Cerebral infarction due to thrombosis of left vertebral artery
- I63.019** Cerebral infarction due to thrombosis of unspecified vertebral artery
- I63.02** Cerebral infarction due to thrombosis of basilar artery
- I63.031** Cerebral infarction due to thrombosis of right carotid artery
- I63.032** Cerebral infarction due to thrombosis of left carotid artery
- I63.039** Cerebral infarction due to thrombosis of unspecified carotid artery
- I63.09** Cerebral infarction due to thrombosis of other precerebral artery
- I63.20** Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries
- I63.211** Cerebral infarction due to unspecified occlusion or stenosis of right vertebral arteries
- I63.212** Cerebral infarction due to unspecified occlusion or stenosis of left vertebral arteries
- I63.219** Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries

Important Safety Information

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Please [click here](#) to see additional Important Safety Information on page 17.

Cerebrovascular Diseases (*cont'd*)

➤ Cerebral infarction (*cont'd*)

- I63.22** Cerebral infarction due to unspecified occlusion or stenosis of basilar arteries
- I63.231** Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries
- I63.232** Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries
- I63.239** Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries
- I63.29** Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries
- I63.30** Cerebral infarction due to thrombosis of unspecified cerebral artery
- I63.311** Cerebral infarction due to thrombosis of right middle cerebral artery
- I63.312** Cerebral infarction due to thrombosis of left middle cerebral artery
- I63.319** Cerebral infarction due to thrombosis of unspecified middle cerebral artery
- I63.321** Cerebral infarction due to thrombosis of right anterior cerebral artery
- I63.322** Cerebral infarction due to thrombosis of left anterior cerebral artery
- I63.329** Cerebral infarction due to thrombosis of unspecified anterior cerebral artery
- I63.331** Cerebral infarction due to thrombosis of right posterior cerebral artery
- I63.332** Cerebral infarction due to thrombosis of left posterior cerebral artery
- I63.339** Cerebral infarction due to thrombosis of unspecified posterior cerebral artery
- I63.341** Cerebral infarction due to thrombosis of right cerebellar artery
- I63.342** Cerebral infarction due to thrombosis of left cerebellar artery
- I63.349** Cerebral infarction due to thrombosis of unspecified cerebellar artery
- I63.39** Cerebral infarction due to thrombosis of other cerebral artery
- I63.50** Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery
- I63.511** Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery
- I63.512** Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery
- I63.519** Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery
- I63.521** Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery
- I63.522** Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery
- I63.529** Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery
- I63.531** Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery
- I63.532** Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery
- I63.539** Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery
- I63.541** Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery
- I63.542** Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery

Important Safety Information

From a pool of the 52-week trial and seven 12-week trials: Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please [click here](#) to see additional Important Safety Information on page 17.

Cerebrovascular Diseases (*cont'd*) and Diseases of Arteries, Arterioles, and Capillaries



- I63.549** Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery
- I63.59** Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery
- I63.8** Other cerebral infarction
- I63.9** Cerebral infarction, unspecified

➤ Transient cerebral ischemic attack

- Z86.73** Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
- G45.8** Other transient cerebral ischemic attacks and related syndromes
- G45.9** Transient cerebral ischemic attack, unspecified

➤ History of transient ischemic attack (TIA) or cerebral infarction without residuals

- Z86.73** Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

➤ Vascular syndromes of brain in cerebrovascular diseases

- G46.0** Middle cerebral artery syndrome
- G46.1** Anterior cerebral artery syndrome

- G46.2** Posterior cerebral artery syndrome
- G46.3** Brain stem stroke syndrome
- G46.4** Cerebellar stroke syndrome
- G46.5** Pure motor lacunar syndrome
- G46.6** Pure sensory lacunar syndrome
- G46.7** Other lacunar syndromes
- G46.8** Other vascular syndromes of brain in cerebrovascular diseases

➤ Atherosclerosis

- I70.0** Atherosclerosis of aorta
- I70.1** Atherosclerosis of renal artery
- I70.201** Unspecified atherosclerosis of native arteries of extremities, right leg
- I70.202** Unspecified atherosclerosis of native arteries of extremities, left leg
- I70.203** Unspecified atherosclerosis of native arteries of extremities, bilateral legs
- I70.208** Unspecified atherosclerosis of native arteries of extremities, other extremity
- I70.209** Unspecified atherosclerosis of native arteries of extremities, unspecified extremity
- I70.211** Atherosclerosis of native arteries of extremities with intermittent claudication, right leg
- I70.212** Atherosclerosis of native arteries of extremities with intermittent claudication, left leg

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: The safety profile of Repatha® in this trial was generally consistent with the safety profile described above in the 12- and 52-week controlled trials involving patients with primary hyperlipidemia (including HeFH). Serious adverse events occurred in 24.8% and 24.7% of Repatha®-treated and placebo-treated patients, respectively. Adverse events led to discontinuation of study treatment in 4.4% of patients assigned to Repatha® and 4.2% assigned to placebo. Common adverse reactions (> 5% of patients treated with Repatha® and occurring more frequently than placebo) included diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



➤ Atherosclerosis (*cont'd*)

- I70.213** Atherosclerosis of native arteries of extremities with intermittent claudication, bilateral legs
- I70.218** Atherosclerosis of native arteries of extremities with intermittent claudication, other extremity
- I70.219** Atherosclerosis of native arteries of extremities with intermittent claudication, unspecified extremity
- I70.221** Atherosclerosis of native arteries of extremities with rest pain, right leg
- I70.222** Atherosclerosis of native arteries of extremities with rest pain, left leg
- I70.223** Atherosclerosis of native arteries of extremities with rest pain, bilateral legs
- I70.228** Atherosclerosis of native arteries of extremities with rest pain, other extremity
- I70.229** Atherosclerosis of native arteries of extremities with rest pain, unspecified extremity
- I70.231** Atherosclerosis of native arteries of right leg with ulceration of thigh
- I70.232** Atherosclerosis of native arteries of right leg with ulceration of calf
- I70.233** Atherosclerosis of native arteries of right leg with ulceration of ankle
- I70.234** Atherosclerosis of native arteries of right leg with ulceration of heel and midfoot
- I70.235** Atherosclerosis of native arteries of right leg with ulceration of other part of foot
- I70.238** Atherosclerosis of native arteries of right leg with ulceration of other part of lower right leg
- I70.239** Atherosclerosis of native arteries of right leg with ulceration of unspecified site
- I70.241** Atherosclerosis of native arteries of left leg with ulceration of thigh
- I70.242** Atherosclerosis of native arteries of left leg with ulceration of calf
- I70.243** Atherosclerosis of native arteries of left leg with ulceration of ankle
- I70.244** Atherosclerosis of native arteries of left leg with ulceration of heel and midfoot
- I70.245** Atherosclerosis of native arteries of left leg with ulceration of other part of foot
- I70.248** Atherosclerosis of native arteries of left leg with ulceration of other part of lower left leg
- I70.249** Atherosclerosis of native arteries of left leg with ulceration of unspecified site
- I70.25** Atherosclerosis of native arteries of other extremities with ulceration
- I70.261** Atherosclerosis of native arteries of extremities with gangrene, right leg
- I70.262** Atherosclerosis of native arteries of extremities with gangrene, left leg
- I70.263** Atherosclerosis of native arteries of extremities with gangrene, bilateral legs
- I70.268** Atherosclerosis of native arteries of extremities with gangrene, other extremity
- I70.269** Atherosclerosis of native arteries of extremities with gangrene, unspecified extremity
- I70.291** Other atherosclerosis of native arteries of extremities, right leg
- I70.292** Other atherosclerosis of native arteries of extremities, left leg
- I70.293** Other atherosclerosis of native arteries of extremities, bilateral legs
- I70.298** Other atherosclerosis of native arteries of extremities, other extremity

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha® compared with 7.7% in those assigned to placebo.

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.299** Other atherosclerosis of native arteries of extremities, unspecified extremity
- I70.301** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- I70.302** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- I70.303** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- I70.308** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- I70.309** Unspecified atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- I70.311** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.312** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.313** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.318** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.319** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.321** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, right leg
- I70.322** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, left leg
- I70.323** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.328** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, other extremity
- I70.329** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.331** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of thigh
- I70.332** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of calf
- I70.333** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of ankle
- I70.334** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.335** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of foot
- I70.338** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.339** Atherosclerosis of unspecified type of bypass graft(s) of the right leg with ulceration of unspecified site
- I70.341** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of thigh
- I70.342** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of calf
- I70.343** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of ankle
- I70.344** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.345** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of foot

Important Safety Information

Adverse Reactions in Homozygous Familial Hypercholesterolemia (HoFH): In 49 patients with HoFH studied in a 12-week, double-blind, randomized, placebo-controlled trial, 33 patients received 420 mg of Repatha® subcutaneously once monthly. The adverse reactions that occurred in at least two (6.1%) Repatha®-treated patients, and more frequently than in placebo-treated patients, included upper respiratory tract infection (9.1% versus 6.3%), influenza (9.1% versus 0%), gastroenteritis (6.1% versus 0%), and nasopharyngitis (6.1% versus 0%).

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



➤ Atherosclerosis (*cont'd*)

- I70.348** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.349** Atherosclerosis of unspecified type of bypass graft(s) of the left leg with ulceration of unspecified site
- I70.35** Atherosclerosis of unspecified type of bypass graft(s) of other extremity with ulceration
- I70.361** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, right leg
- I70.362** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, left leg
- I70.363** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.368** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, other extremity
- I70.369** Atherosclerosis of unspecified type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.391** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, right leg
- I70.392** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, left leg
- I70.393** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, bilateral legs
- I70.398** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, other extremity
- I70.399** Other atherosclerosis of unspecified type of bypass graft(s) of the extremities, unspecified extremity
- I70.401** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.402** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.403** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.408** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.409** Unspecified atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.411** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.412** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.413** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.418** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.419** Atherosclerosis of autologous vein bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.421** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, right leg
- I70.422** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, left leg
- I70.423** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.428** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, other extremity
- I70.429** Atherosclerosis of autologous vein bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.431** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of thigh
- I70.432** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of calf
- I70.433** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of ankle
- I70.434** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of heel and midfoot

Important Safety Information

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.435** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of foot
- I70.438** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.439** Atherosclerosis of autologous vein bypass graft(s) of the right leg with ulceration of unspecified site
- I70.441** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of thigh
- I70.442** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of calf
- I70.443** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of ankle
- I70.444** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.445** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of foot
- I70.448** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.449** Atherosclerosis of autologous vein bypass graft(s) of the left leg with ulceration of unspecified site
- I70.45** Atherosclerosis of autologous vein bypass graft(s) of other extremity with ulceration
- I70.461** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, right leg
- I70.462** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, left leg
- I70.463** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.468** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, other extremity
- I70.469** Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.491** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, right leg
- I70.492** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, left leg
- I70.493** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, bilateral legs
- I70.498** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, other extremity
- I70.499** Other atherosclerosis of autologous vein bypass graft(s) of the extremities, unspecified extremity
- I70.501** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.502** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.503** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs

Important Safety Information

Allergic Reactions: Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)

➤ **Atherosclerosis** (*cont'd*)

- 170.508** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- 170.509** Unspecified atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- 170.511** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, right leg
- 170.512** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, left leg
- 170.513** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- 170.518** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, other extremity
- 170.519** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- 170.521** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, right leg
- 170.522** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, left leg
- 170.523** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, bilateral legs
- 170.528** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, other extremity
- 170.529** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with rest pain, unspecified extremity
- 170.531** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of thigh
- 170.532** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of calf
- 170.533** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of ankle
- 170.534** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of heel and midfoot
- 170.535** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of foot
- 170.538** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of other part of lower leg
- 170.539** Atherosclerosis of nonautologous biological bypass graft(s) of the right leg with ulceration of unspecified site
- 170.541** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of thigh
- 170.542** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of calf
- 170.543** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of ankle
- 170.544** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of heel and midfoot
- 170.545** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of foot
- 170.548** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of other part of lower leg
- 170.549** Atherosclerosis of nonautologous biological bypass graft(s) of the left leg with ulceration of unspecified site
- 170.55** Atherosclerosis of nonautologous biological bypass graft(s) of other extremity with ulceration
- 170.561** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, right leg
- 170.562** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, left leg
- 170.563** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, bilateral legs

Important Safety Information

Adverse Reactions in Primary Hyperlipidemia, including HeFH: The most common adverse reactions (> 5% of Repatha[®]-treated patients and occurring more frequently than placebo) in clinical trials in primary hyperlipidemia (including HeFH) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.568** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, other extremity
- I70.569** Atherosclerosis of nonautologous biological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.591** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, right leg
- I70.592** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, left leg
- I70.593** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, bilateral legs
- I70.598** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, other extremity
- I70.599** Other atherosclerosis of nonautologous biological bypass graft(s) of the extremities, unspecified extremity
- I70.601** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.602** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.603** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.608** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.609** Unspecified atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.611** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.612** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.613** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.618** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, other extremity
- I70.619** Atherosclerosis of nonbiological bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.621** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, right leg
- I70.622** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, left leg
- I70.623** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.628** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, other extremity
- I70.629** Atherosclerosis of nonbiological bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.631** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of thigh
- I70.632** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of calf
- I70.633** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of ankle

Important Safety Information

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



➤ Atherosclerosis (*cont'd*)

- I70.634** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.635** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of foot
- I70.638** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.639** Atherosclerosis of nonbiological bypass graft(s) of the right leg with ulceration of unspecified site
- I70.641** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of thigh
- I70.642** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of calf
- I70.643** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of ankle
- I70.644** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.645** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of foot
- I70.648** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.649** Atherosclerosis of nonbiological bypass graft(s) of the left leg with ulceration of unspecified site
- I70.65** Atherosclerosis of nonbiological bypass graft(s) of other extremity with ulceration
- I70.661** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, right leg
- I70.662** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, left leg
- I70.663** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.668** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, other extremity
- I70.669** Atherosclerosis of nonbiological bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.691** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, right leg
- I70.692** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, left leg
- I70.693** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, bilateral legs
- I70.698** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, other extremity
- I70.699** Other atherosclerosis of nonbiological bypass graft(s) of the extremities, unspecified extremity
- I70.701** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.702** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.703** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.708** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.709** Unspecified atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.711** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, right leg
- I70.712** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, left leg
- I70.713** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, bilateral legs
- I70.718** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, other extremity

Important Safety Information

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)



- I70.719** Atherosclerosis of other type of bypass graft(s) of the extremities with intermittent claudication, unspecified extremity
- I70.721** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, right leg
- I70.722** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, left leg
- I70.723** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, bilateral legs
- I70.728** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, other extremity
- I70.729** Atherosclerosis of other type of bypass graft(s) of the extremities with rest pain, unspecified extremity
- I70.731** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of thigh
- I70.732** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of calf
- I70.733** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of ankle
- I70.734** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of heel and midfoot
- I70.735** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of foot
- I70.738** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of other part of lower leg
- I70.739** Atherosclerosis of other type of bypass graft(s) of the right leg with ulceration of unspecified site
- I70.741** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of thigh
- I70.742** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of calf
- I70.743** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of ankle
- I70.744** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of heel and midfoot
- I70.745** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of foot
- I70.748** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of other part of lower leg
- I70.749** Atherosclerosis of other type of bypass graft(s) of the left leg with ulceration of unspecified site
- I70.75** Atherosclerosis of other type of bypass graft(s) of other extremity with ulceration
- I70.761** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, right leg
- I70.762** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, left leg
- I70.763** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, bilateral legs
- I70.768** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, other extremity

Important Safety Information

From a pool of the 52-week trial and seven 12-week trials: Allergic reactions occurred in 5.1% and 4.7% of Repatha[®]-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha[®] and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Please [click here](#) to see additional Important Safety Information on page 17.

Diseases of Arteries, Arterioles, and Capillaries (*cont'd*)

➤ **Atherosclerosis (*cont'd*)**

- I70.769** Atherosclerosis of other type of bypass graft(s) of the extremities with gangrene, unspecified extremity
- I70.791** Other atherosclerosis of other type of bypass graft(s) of the extremities, right leg
- I70.792** Other atherosclerosis of other type of bypass graft(s) of the extremities, left leg
- I70.793** Other atherosclerosis of other type of bypass graft(s) of the extremities, bilateral legs
- I70.798** Other atherosclerosis of other type of bypass graft(s) of the extremities, other extremity
- I70.799** Other atherosclerosis of other type of bypass graft(s) of the extremities, unspecified extremity
- I70.8** Atherosclerosis of other arteries
- I70.90** Unspecified atherosclerosis
- I70.91** Generalized atherosclerosis
- I70.92** Chronic total occlusion of artery of the extremities

➤ **Diseases of arteries, arterioles, and capillaries (other)**

- I73.9** Peripheral vascular disease, unspecified

➤ **Family History**

- Z83.42** Family history of familial hypercholesterolemia

➤ **Peripheral vascular angioplasty**

- Z95.820** Peripheral vascular angioplasty status with implants and grafts
- Z98.62** Peripheral vascular angioplasty status

➤ **Other lipid storage disorders**

- E75.5** Other lipid storage disorders*

* Other lipid storage disorders include tendon xanthoma.

Important Safety Information

Adverse Reactions in the Cardiovascular Outcomes Trial: The safety profile of Repatha[®] in this trial was generally consistent with the safety profile described above in the 12- and 52-week controlled trials involving patients with primary hyperlipidemia (including HeFH). Serious adverse events occurred in 24.8% and 24.7% of Repatha[®]-treated and placebo-treated patients, respectively. Adverse events led to discontinuation of study treatment in 4.4% of patients assigned to Repatha[®] and 4.2% assigned to placebo. Common adverse reactions (> 5% of patients treated with Repatha[®] and occurring more frequently than placebo) included diabetes mellitus (8.8% Repatha[®], 8.2% placebo), nasopharyngitis (7.8% Repatha[®], 7.4% placebo), and upper respiratory tract infection (5.1% Repatha[®], 4.8% placebo).

Please [click here](#) to see additional Important Safety Information on page 17.

Important Safety Information:

- **Contraindication:** Repatha[®] is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha[®].
- **Allergic Reactions:** Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients treated with Repatha[®], including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha[®], treat according to the standard of care, and monitor until signs and symptoms resolve.
- **Adverse Reactions in Primary Hyperlipidemia, including HeFH:** The most common adverse reactions (> 5% of Repatha[®]-treated patients and occurring more frequently than placebo) in clinical trials in primary hyperlipidemia (including HeFH) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha[®]-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha[®] treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha[®] and placebo, respectively).

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha[®]-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha[®]-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha[®]-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha[®] and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).
- **Adverse Reactions in the Cardiovascular Outcomes Trial:** The safety profile of Repatha[®] in this trial was generally consistent with the safety profile described above in the 12- and 52-week controlled trials involving patients with primary hyperlipidemia (including HeFH). Serious adverse events occurred in 24.8% and 24.7% of Repatha[®]-treated and placebo-treated patients, respectively. Adverse events led to discontinuation of study treatment in 4.4% of patients assigned to Repatha[®] and 4.2% assigned to placebo. Common adverse reactions (> 5% of patients treated with Repatha[®] and occurring more frequently than placebo) included diabetes mellitus (8.8% Repatha[®], 8.2% placebo), nasopharyngitis (7.8% Repatha[®], 7.4% placebo), and upper respiratory tract infection (5.1% Repatha[®], 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients assigned to Repatha[®] compared with 7.7% in those assigned to placebo.
- **Adverse Reactions in Homozygous Familial Hypercholesterolemia (HoFH):** In 49 patients with HoFH studied in a 12-week, double-blind, randomized, placebo-controlled trial, 33 patients received 420 mg of Repatha[®] subcutaneously once monthly. The adverse reactions that occurred in at least two (6.1%) Repatha[®]-treated patients, and more frequently than in placebo-treated patients, included upper respiratory tract infection (9.1% versus 6.3%), influenza (9.1% versus 0%), gastroenteritis (6.1% versus 0%), and nasopharyngitis (6.1% versus 0%).
- **Immunogenicity:** Repatha[®] is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha[®].

Reference: Centers for Medicare & Medicaid Services. 2018 ICD-10 Codes Table and Index.

Please [click here](#) to see full Prescribing Information.

AMGEN[®]

Amgen
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

© 2018 Amgen Inc. All rights reserved. USA-145-127284(3) 01-18

 **Repatha**[®]
(evolocumab) injection
140 mg/mL